Published in Novartis Found Symp on January 01, 2003
Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity (2008) 6.08
Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest (2006) 2.73
Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy. Immunol Rev (2009) 1.19
Discovery of a novel series of inhibitors of lymphoid tyrosine phosphatase with activity in human T cells. J Med Chem (2011) 1.00
Genetic-induced variations in the GAD65 T-cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset type 1 diabetes. Mol Ther (2009) 0.95
Immune intervention in type 1 diabetes. Semin Immunol (2011) 0.94
Tolerance induction and endogenous regeneration of pancreatic beta-cells in established autoimmune diabetes. Rev Diabet Stud (2005) 0.75
Immunotherapy after recent-onset type 1 diabetes: combinatorial treatment for achieving long-term remission in humans? Rev Diabet Stud (2004) 0.75
Age-related Defects in Ocular and Nasal Mucosal Immune System and the Immunopathology of Dry Eye Disease. Ocul Immunol Inflamm (2014) 0.75